https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Factors Associated With Placebo Treatment Response in Functional Dyspepsia Clinical Trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50841 Wed 09 Aug 2023 09:10:43 AEST ]]> Wheat intolerance and chronic gastrointestinal symptoms in an Australian population-based study: association between wheat sensitivity, celiac disease and functional gastrointestinal disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36106 Wed 06 Apr 2022 13:57:21 AEST ]]> Electroencephalographic evidence of unconscious and conscious attentional bias in people with functional gastrointestinal disorders: A pilot study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49759 Tue 30 May 2023 18:25:04 AEST ]]> Overlap of disorders of gut–brain interaction: a systematic review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52364 Tue 10 Oct 2023 14:16:58 AEDT ]]> Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46015 0.5). Conclusions: In FD patients, the response to antimicrobial therapy with rifaximin is not influenced by concomitant IBS symptoms.]]> Tue 08 Nov 2022 18:38:07 AEDT ]]> Wheat sensitivity and functional dyspepsia: A pilot, double-blind, randomized, placebo-controlled dietary crossover trial with novel challenge protocol https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45328 30% response to the run-in diet, as measured by the Nepean Dyspepsia Index, were then re-challenged with 'muesli' bars containing either gluten, fructan, or placebo in randomised order. Those with symptoms which significantly reduced during the elimination diet, but reliably reappeared (a mean change in overall dyspeptic symptoms of >30%) with gluten or fructan re-challenge were deemed to have wheat induced FD. Results: Eleven participants were enrolled in the study (75% female, mean age 43 years). Of the initial cohort, nine participants completed the elimination diet phase of whom four qualified for the rechallenge phase. The gluten-free, low FODMAP diet led to an overall (albeit non-significant) improvement in symptoms of functional dyspepsia in the diet elimination phase (mean NDI symptom score 71.2 vs. 47.1, p = 0.087). A specific food trigger could not be reliably demonstrated. Conclusions: Although a gluten-free, low-FODMAP diet led to a modest overall reduction in symptoms in this cohort of FD patients, a specific trigger could not be identified. The modified Salerno criteria for NCG/WS identification trialled in this dietary rechallenge protocol was fit-for-purpose. However, larger trials are required to determine whether particular components of wheat induce symptoms in functional dyspepsia.]]> Thu 27 Oct 2022 08:44:08 AEDT ]]> Management of early anal cancer: need for guidelines and standardisation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33908 Thu 27 Jan 2022 15:58:48 AEDT ]]> The impact of contour variation on tumour control probability in anal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32548 Thu 24 Mar 2022 11:30:42 AEDT ]]> The duodenal mucosa associated microbiome, visceral sensory function, immune activation and psychological comorbidities in functional gastrointestinal disorders with and without self-reported non-celiac wheat sensitivity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51213 Thu 24 Aug 2023 14:59:28 AEST ]]> Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41177 Thu 18 Apr 2024 12:11:34 AEST ]]> Duodenal Eosinophils and Mast Cells in Functional Dyspepsia: A Systematic Review and Meta-Analysis of Case-Control Studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50280 Thu 13 Jul 2023 10:29:20 AEST ]]> An increasing incidence of upper gastrointestinal disorders over 23 years: A prospective population-based study in Sweden https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46068 Thu 10 Nov 2022 14:23:04 AEDT ]]> Overlap of heartburn, functional dyspepsia, and irritable bowel syndrome in a population sample: Prevalence, temporal stability, and associated comorbidities https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48154 Thu 09 Mar 2023 09:37:46 AEDT ]]> The Nepean Dyspepsia Index is a valid instrument for measuring quality-of-life in functional dyspepsia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36103 0.5) standardized loadings on their respective latent variables and all reached statistical significance (P<0.0001), supporting their relationships with the hypothesized domains. Convergent validity was strongly supported, with every domain being correlated with multiple external instruments; the majority of correlations were in the range 0.3-0.5 (in absolute values). The items comprising each domain showed good internal consistency, with the lowest value of Chronbach α at 0.80. Scores based on the short form (10-item) version of the NDI correlated strongly with the full 25-item form (tension ρ=0.88, interference ρ=0.94, eat/drink ρ=0.95, knowledge ρ=0.84 and work/study ρ=0.97; all P<0.0001). Conclusion: The NDI is a valid instrument that can be used to measure the disease-specific impact of FD on quality of life.]]> Thu 06 Feb 2020 13:08:06 AEDT ]]> Limited evidence of moderation of the association between gastrointestinal symptoms and prospective healthcare utilisation by quality of life https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46842 Thu 01 Dec 2022 16:04:34 AEDT ]]> Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48476 Sun 19 Mar 2023 15:13:30 AEDT ]]> Understanding statistical principles in correlation, causation and moderation in human disease https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31219 Sat 24 Mar 2018 08:43:21 AEDT ]]> What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome?: are current IBS symptom thresholds clinically meaningful? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12771 43 and >48) and ‘impaired’ functioning (defined as a score of ≤43 and ≤48), respectively. Psychological variables were assessed via valid self-report. Results: Having ‘more’ versus ‘less’ severe abdominal pain (OR = 9.41; 95% CI 1.17–75.43, P = 0.03) and ‘more’ versus ‘less’ frequent diarrhoea (OR = 2.19; 95% CI 1.13–4.26, P = 0.02) along with increasing age (OR = 1.03; 95% CI 1.01–1.05, P = 0.003) were significant independent predictors of having impairment in physical functioning. In terms of psychological factors, having higher levels of depression (OR = 1.61; 95% CI 1.36–1.91) and somatic distress (OR = 1.17; 95% CI 1.09–1.27) were independently associated with mental and physical impairment, respectively. Conclusion: The current frequency and severity threshold cut-offs for IBS symptoms in the Rome III criteria are associated with a clinically meaningful impairment of quality of life in community subjects with IBS.]]> Sat 24 Mar 2018 08:18:20 AEDT ]]> Novel biomarker panel for the irritable bowel syndrome: a diagnostic blood test is promising https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13237 Sat 24 Mar 2018 08:17:36 AEDT ]]> Role of personality in medical students' initial intention to become rural doctors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17319 Sat 24 Mar 2018 08:01:45 AEDT ]]> Early life factors initiate a 'vicious circle' of affective and gastrointestinal symptoms: a longitudinal study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17257 Sat 24 Mar 2018 08:01:24 AEDT ]]> Aiming for the truth: understanding the difference between validity and precision https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29272 Sat 24 Mar 2018 07:39:16 AEDT ]]> Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27132 Brachyspira in colonic biopsies, is uncommon and considered of doubtful significance. We aimed to determine the prevalence of CS in the general population, identify subtle colon pathologies, and evaluate a link with symptoms of IBS. Colonoscopy was performed in 745 subjects (aged 19-70 years, mean age 51 years, 43% male) with biopsies (ileum and 4 colonic sites) from a random population sample, Stockholm, Sweden, who completed a validated questionnaire of gastrointestinal symptoms; IBS was identified by Rome III criteria. CS was identified by histology and immunohistochemistry. In a general population, 17 individuals (2.28%; 95% confidence interval, 1.2%-3.5%) were diagnosed as having CS by histology; 6 (35%) had IBS. CS was always present in the sigmoid colon, but only 14 rectal biopsies. Eosinophils were increased in colon biopsies in CS cases versus controls, in the transverse (P =.02), sigmoid colon (P =.001), and rectum (P =.0005) with subepithelial eosinophil clusters (P =.053). Lymphoid follicles (at any site) were present in 13 CS (P =.0003). There was a 3-fold increased risk of IBS in CS (odds ratio, 3.59; 95% confidence interval, 1.27-10.11; P =.015). Polyps and diverticular disease were similar in CS cases and controls. The prevalence of CS in a general population is 2% and associated with nonconstipating IBS. Colonic eosinophilia with lymphoid follicles may signify the presence of CS.]]> Sat 24 Mar 2018 07:33:02 AEDT ]]> Multi-dimensional gastrointestinal symptom severity index: validation of a brief GI symptom assessment tool https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28111 a priori hypothesized six-factor measurement model (X²(428) = 1462.98; P<0.001; GFI = .88; RMSEA = .051). Conclusion: The GISSI demonstrated good to excellent psychometric properties and provided multi-dimensional scaling of prominent GI symptom clusters. Further validation may provide an efficient, valid, and reliable measure of patient-reported clinical outcomes.]]> Sat 24 Mar 2018 07:25:00 AEDT ]]> Development and Validation of a Patient-Reported Experience Measure for Gastrointestinal Endoscopy: The Comprehensive Endoscopy Satisfaction Tool (CEST) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51261 Mon 28 Aug 2023 14:59:19 AEST ]]> Understanding women who self-harm: predictors and long-term outcomes in a longitudinal community sample https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32613 Mon 25 Jun 2018 14:21:11 AEST ]]> Effects of psychology and extragastrointestinal symptoms on health care use by subjects with and without irritable bowel syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48303 Mon 15 May 2023 10:42:18 AEST ]]> Antibiotic use but not gastrointestinal infection frequently precedes first diagnosis of functional gastrointestinal disorders https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46215 Mon 14 Nov 2022 12:04:53 AEDT ]]> Healthcare Needs and Perceptions of People Living with Inflammatory Bowel Disease in Australia: A Mixed-Methods Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48208 Mon 08 May 2023 15:57:15 AEST ]]> Evaluation of a Multidisciplinary Integrated Treatment Approach Versus Standard Model of Care for Functional Gastrointestinal Disorders (FGIDS): A Matched Cohort Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51423 Mon 04 Sep 2023 14:58:08 AEST ]]> Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34348 Mon 04 Mar 2019 14:57:54 AEDT ]]> Incidence and prevalence of self-reported non-coeliac wheat sensitivity and gluten avoidance in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40013 Mon 04 Jul 2022 08:54:31 AEST ]]> Gastrointestinal recall questionnaires compare poorly with prospective patient diaries for gastrointestinal symptoms: Data from population and primary health centre samples https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43800 Fri 30 Sep 2022 14:43:44 AEST ]]> Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: a systematic review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45460 P = .37) but was significantly more prevalent in IBS-C as compared to IBS-D (OR = 3.1, 95% CI 1.7–5.6, P = .0001). The prevalence of methane-positive SIBO in patients with IBD was 3-fold lower at 7.4% (95% CI 5.4–9.8) compared to 23.5% (95% CI 19.8–27.5) in controls. The prevalence of methane positive SIBO was significantly lower in Crohn’s disease as compared to ulcerative colitis, (5.3%, 95% CI 3.0–8.5 vs. 20.2%, 95% CI 12.8–29.4). This systematic review and meta-analysis suggests methane positivity on breath testing is positively associated with IBS-C and inversely with IBD. However, the quality of evidence is low largely due to clinical heterogeneity of the studies. Thus, causality is uncertain and further studies are required.]]> Fri 28 Oct 2022 14:29:23 AEDT ]]> Ileocolonic histopathological and microbial alterations in the irritable bowel syndrome: a nested community case-control study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39241 P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS—diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13–3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. Discussion: A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.]]> Fri 27 May 2022 14:39:27 AEST ]]> Understanding statistical hypothesis tests and power https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33959 Fri 25 Jan 2019 11:54:05 AEDT ]]> Clusters of community-dwelling individuals empirically derived from stool diaries correspond with clinically meaningful outcomes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49999 Fri 23 Jun 2023 11:40:47 AEST ]]> Sampling: how you choose people is as important as how you analyse their data https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34521 Fri 22 Mar 2019 12:59:23 AEDT ]]> Small Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-Analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49370 Fri 12 May 2023 13:38:14 AEST ]]> Routine assessment of gastrointestinal symptom using a validated questionnaire in the clinical setting to assess the probability of organic or functional gastrointestinal diseases https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49104 Fri 05 May 2023 11:32:06 AEST ]]> The role of mood state and emotion regulation in the discrepancy between gastrointestinal symptom burden recorded prospectively and via recall questionnaire https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45748 Fri 04 Nov 2022 10:26:56 AEDT ]]>